{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:00:08Z","timestamp":1762376408228},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s41999-018-0071-1","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T12:52:12Z","timestamp":1528980732000},"page":"415-418","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medicines for older people: assessment and transparency at the European Medicines Agency regarding cardiovascular and antithrombotic medicinal products"],"prefix":"10.1007","volume":"9","author":[{"given":"Francesca","family":"Cerreta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"Padr\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Skibicka-Stepien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Strampelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Silvia","family":"de Orbe Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"71_CR1","unstructured":"United Nations. World Population Ageing 2015. \n                    http:\/\/www.un.org\/en\/development\/desa\/population\/publications\/pdf\/ageing\/WPA2015_Report.pdf\n                    \n                   Accessed 14 Dec 2017"},{"issue":"6","key":"71_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","volume":"171","author":"A Cherubini","year":"2011","unstructured":"Cherubini A, Oristrell J, Pla X et al (2011) The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart Failure. Arch Intern Med 171(6):550\u2013556","journal-title":"Arch Intern Med"},{"key":"71_CR3","unstructured":"National Report on Medicines use in Italy. Year 2015 (English edition)"},{"key":"71_CR4","unstructured":"http:\/\/www.aifa.gov.it\/content\/national-report-medicines-use-italy-year-2015-english-edition\n                    \n                   Accessed 23 Feb 2018"},{"key":"71_CR5","unstructured":"EudraVigilance. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000679.jsp&mid=WC0b01ac05800250b5\n                    \n                   Accessed 30 Nov 2017"},{"key":"71_CR6","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMp1209034","volume":"367","author":"F Cerreta","year":"2012","unstructured":"Cerreta F, Hans-Georg E, Rasi G (2012) Drug policy for an aging population\u2014the European medicines agency geriatric medicines strategy. N Engl J Med 367:1972\u20131974","journal-title":"N Engl J Med"},{"key":"71_CR7","doi-asserted-by":"publisher","first-page":"j510","DOI":"10.1136\/bmj.j510","volume":"356","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skj\u00f8th F, S\u00f8gaard M, Kj\u00e6ldgaard JN, Lip GYH, Larsen TB (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356:j510","journal-title":"BMJ"},{"issue":"6","key":"71_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/pds.4203","volume":"26","author":"ME Nyeland","year":"2017","unstructured":"Nyeland ME, Laursen MV, Callr\u00e9us T (2017) Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data. Pharmacoepidemiol Drug Saf 26(6):607\u2013614","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"71_CR9","unstructured":"European Medicines Agency. Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/clinical_general\/general_content_001232.jsp&mid=WC0b01ac0580032ec4\n                    \n                   Accessed 23 Feb 2018"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41999-018-0071-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-018-0071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-018-0071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T23:23:50Z","timestamp":1560468230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41999-018-0071-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s41999-018-0071-1","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare that they have no conflict of interest. Andreia Padr\u00e3o was working at the European Medicines Agency when the study was carried out.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}